Company intelligence / Profile preview

Tetranov Pharmaceutical

Zhengzhou, Henan, China

Ownership: Private
Development stage: Other

Overview

Tetranov Biopharma is a clinical-stage biotechnology company dedicated to the discovery and development of innovative small molecule drugs and protein degradation therapies. The company utilizes its proprietary Tetra-PROTAC platform to design highly selective and potent candidates for oncology and autoimmune indications. Its lead program, T-001, is a next-generation Bruton tyrosine kinase (BTK) inhibitor currently in clinical development for B-cell malignancies. Tetranov is headquartered in Zhengzhou, China, and maintains a focus on addressing drug resistance and improving therapeutic outcomes for patients with complex diseases.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculeProteolysis-targeting chimera therapy
Industry: Biotech

Beyond the preview

Go deeper on Tetranov Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tetranov Pharmaceutical.

Explore the full profile